Formulation of nanoparticle-eluting stents by a cationic electrodeposition coating technology: efficient nano-drug delivery via bioabsorbable polymeric nanoparticle-eluting stents in porcine coronary arteries. | |
MedLine Citation:
|
PMID: 19463437 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: The objective of this study was to formulate a nanoparticle (NP)-eluting drug delivery stent system by a cationic electrodeposition coating technology. BACKGROUND: Nanoparticle-mediated drug delivery systems (DDS) are poised to transform the development of innovative therapeutic devices. Therefore, we hypothesized that a bioabsorbable polymeric NP-eluting stent provides an efficient DDS that shows better and more prolonged delivery compared with dip-coating stent. METHODS: We prepared cationic NP encapsulated with a fluorescence marker (FITC) by emulsion solvent diffusion method, succeeded to formulate an NP-eluting stent with a novel cation electrodeposition coating technology, and compared the in vitro and in vivo characteristics of the FITC-loaded NP-eluting stent with dip-coated FITC-eluting stent and bare metal stent. RESULTS: The NP was taken up stably and efficiently by cultured vascular smooth muscle cells in vitro. In a porcine coronary artery model in vivo, substantial FITC fluorescence was observed in neointimal and medial layers of the stented segments that had received the FITC-NP-eluting stent until 4 weeks. In contrast, no substantial FITC fluorescence was observed in the segments from the polymer-based FITC-eluting stent or from bare metal stent. The magnitudes of stent-induced injury, inflammation, endothelial recovery, and neointima formation were comparable between bare metal stent and NP-eluting stent groups. CONCLUSIONS: Therefore, this NP-eluting stent is an efficient NP-mediated DDS that holds as an innovative platform for the delivery of less invasive nano-devices targeting cardiovascular disease. |
Authors:
|
Kaku Nakano; Kensuke Egashira; Seigo Masuda; Kouta Funakoshi; Gang Zhao; Satoshi Kimura; Tetsuya Matoba; Katsuo Sueishi; Yasuhisa Endo; Yoshiaki Kawashima; Kaori Hara; Hiroyuki Tsujimoto; Ryuji Tominaga; Kenji Sunagawa |
Related Documents
:
|
22023937 - Long-term influence of suprarenal or infrarenal fixation on proximal neck dilatation an... 9076767 - Dobutamine 99tcm-mibi spet myocardial perfusion scintigraphy in the prediction of reste... 10467067 - Focal wall overstretching after high-pressure coronary stent implantation does not infl... 20436707 - Effects of combined therapy with ezetimibe plus simvastatin after drug-eluting stent im... 19198007 - Complete versus partial distal embolic protection during renal artery stenting. 22155117 - Emergent angioplasty and stent placement recanalization without thrombolysis in acute m... |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: JACC. Cardiovascular interventions Volume: 2 ISSN: 1876-7605 ISO Abbreviation: JACC Cardiovasc Interv Publication Date: 2009 Apr |
Date Detail:
|
Created Date: 2009-05-25 Completed Date: 2009-08-03 Revised Date: 2014-09-05 |
Medline Journal Info:
|
Nlm Unique ID: 101467004 Medline TA: JACC Cardiovasc Interv Country: United States |
Other Details:
|
Languages: eng Pagination: 277-83 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
MeSH Terms | |
Descriptor/Qualifier:
|
Absorbable Implants* Angioplasty, Balloon, Coronary / adverse effects, instrumentation* Animals Cardiovascular Agents / administration & dosage*, metabolism Cations Cells, Cultured Coated Materials, Biocompatible* Coronary Restenosis / etiology, prevention & control Coronary Vessels / metabolism*, pathology Drug-Eluting Stents* Feasibility Studies Fluorescein-5-isothiocyanate / metabolism Fluorescent Dyes / metabolism Humans Kinetics Lactic Acid / chemistry*, toxicity Male Materials Testing Models, Animal Muscle, Smooth, Vascular / metabolism Nanoparticles* Polyglycolic Acid / chemistry*, toxicity Prosthesis Design Stainless Steel* Sus scrofa |
Chemical | |
Reg. No./Substance:
|
0/Cardiovascular Agents; 0/Cations; 0/Coated Materials, Biocompatible; 0/Fluorescent Dyes; 0/polylactic acid-polyglycolic acid copolymer; 12597-68-1/Stainless Steel; 26009-03-0/Polyglycolic Acid; 33X04XA5AT/Lactic Acid; I223NX31W9/Fluorescein-5-isothiocyanate |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Pulmonary vein stenosis complicating ablation for atrial fibrillation: clinical spectrum and interve...
Next Document: Lowering the dose of sirolimus, released from a nonpolymeric hydroxyapatite coated coronary stent, r...